Ser2101
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser2101  -  SHARP (human)

Site Information
KNVDAAVsPRGAAAQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 452926
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 19 , 20 , 21 , 22 , 23 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 )
Disease tissue studied:
breast cancer ( 5 , 6 , 21 , 22 ) , breast ductal carcinoma ( 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 5 ) , cervical cancer ( 32 ) , cervical adenocarcinoma ( 32 ) , leukemia ( 25 , 37 ) , acute myelogenous leukemia ( 25 ) , chronic myelogenous leukemia ( 37 ) , lung cancer ( 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 22 ) , non-small cell lung cancer ( 8 , 9 , 10 , 12 , 13 , 14 , 22 ) , non-small cell lung adenocarcinoma ( 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ) , non-small cell large cell lung carcinoma ( 9 , 12 ) , non-small cell squamous cell lung carcinoma ( 11 ) , small-cell lung cancer ( 7 ) , neuroblastoma ( 20 ) , melanoma skin cancer ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 31 ) , 293 (epithelial) [AT1 (human), transfection] ( 30 ) , 293E (epithelial) ( 26 ) , A549 (pulmonary) ( 8 , 16 ) , breast ( 1 , 5 ) , BT-20 (breast cell) ( 22 ) , BT-549 (breast cell) ( 22 ) , Cal-12T (pulmonary) ( 14 ) , Calu-3 (pulmonary) ( 10 ) , DMS153 (pulmonary) ( 13 ) , DMS53 (pulmonary) ( 7 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 23 ) , Flp-In T-Rex-293 (epithelial) ( 23 ) , H2009 (pulmonary) ( 22 ) , H2077 (pulmonary) ( 22 ) , H2887 (pulmonary) ( 22 ) , H322M (pulmonary) ( 22 ) , HCC1359 (pulmonary) ( 22 ) , HCC15 (pulmonary) ( 11 ) , HCC366 (pulmonary) ( 22 ) , HCC4006 (pulmonary) ( 22 ) , HCC44 (pulmonary) ( 14 ) , HCC78 (pulmonary) ( 12 , 22 ) , HCC827 (pulmonary) ( 10 , 22 ) , HeLa (cervical) ( 4 , 19 , 29 , 36 , 39 , 40 , 41 ) , HeLa S3 (cervical) ( 27 , 32 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 6 ) , HMLER ('stem, breast cancer') ( 6 ) , HOP62 (pulmonary) ( 22 ) , HUES-9 ('stem, embryonic') ( 28 ) , Jurkat (T lymphocyte) ( 17 , 34 , 35 , 38 ) , K562 (erythroid) ( 19 , 33 , 37 ) , KG-1 (myeloid) ( 25 ) , LCLC-103H (pulmonary) ( 22 ) , LOU-NH91 (squamous) ( 11 , 22 ) , lung ( 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ) , MDA-MB-231 (breast cell) ( 22 ) , MDA-MB-468 (breast cell) ( 22 ) , NB10 (neural crest) ( 20 ) , NCI-H1299 (pulmonary) ( 9 ) , NCI-H1355 (pulmonary) ( 8 ) , NCI-H1395 (pulmonary) ( 22 ) , NCI-H1437 (pulmonary) ( 13 , 14 ) , NCI-H157 (pulmonary) ( 22 ) , NCI-H1650 (pulmonary) ( 10 ) , NCI-H1666 (pulmonary) ( 14 , 22 ) , NCI-H1703 (squamous) ( 11 ) , NCI-H1734 (pulmonary) ( 9 ) , NCI-H1781 (pulmonary) ( 12 ) , NCI-H1792 (pulmonary) ( 8 ) , NCI-H1944 (pulmonary) ( 9 ) , NCI-H1975 (pulmonary) ( 10 ) , NCI-H2030 (pulmonary) ( 22 ) , NCI-H2073 (pulmonary) ( 11 , 13 ) , NCI-H209 (pulmonary) ( 13 ) , NCI-H2106 (pulmonary) ( 10 ) , NCI-H2228 (pulmonary) ( 12 ) , NCI-H23 (pulmonary) ( 8 ) , NCI-H2342 (pulmonary) ( 11 ) , NCI-H2405 (pulmonary) ( 14 ) , NCI-H3122 (pulmonary) ( 12 ) , NCI-H322 (pulmonary) ( 22 ) , NCI-H358 (pulmonary) ( 9 ) , NCI-H441 (pulmonary) ( 8 ) , NCI-H446 (pulmonary) ( 7 ) , NCI-H460 (pulmonary) ( 9 , 22 ) , NCI-H520 (squamous) ( 22 ) , NCI-H526 (pulmonary) ( 7 ) , NCI-H661 (pulmonary) ( 12 ) , NCI-H69 (pulmonary) ( 7 ) , NCI-H82 (pulmonary) ( 7 ) , NCI-H838 (pulmonary) ( 13 ) , NPC (neural crest) ( 20 ) , PC9 (pulmonary) ( 22 ) , SKBr3 (breast cell) ( 21 ) , WM239A (melanocyte) ( 3 )

Upstream Regulation
Treatments:
nocodazole ( 32 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

3

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

4

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

5

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

6

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

9

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

10

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

11

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

12

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

13

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

14

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

15

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

16

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

17

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

18

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

19

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

20

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

21

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

22

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

23

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

24

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

25

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

26

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

27

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

28

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

29

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

30

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

31

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

32

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

33

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

34

Possemato A (2009) CST Curation Set: 6371; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

35

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

36

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

37

Stokes M (2008) CST Curation Set: 4392; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

38

Possemato A (2007) CST Curation Set: 2796; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate Motif (pS/pTQG) Antibody Cat#: 5074, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQG) Immunoaffinity Beads Cat#: 1993
Curated Info

39

Olsen JV, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-48
17081983   Curated Info

40

Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92
16964243   Curated Info

41

Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5
15302935   Curated Info